Abstract: Disclosed herein are methods and devices for a cell-free assay platform that enables measurement of membrane protein function by measuring the events that are induced by ligand binding or other stimuli.

Abstract: Devices and methods for detecting the presence or absence and/or one or more characteristics of analytes are disclosed. Embodiments of the disclosed devices include an actuator having a staging reservoir which can be operably connected with an electrophoresis assembly. In some embodiments, the disclosed methods include operating the subject devices, for example, by actuating the actuator to operably connect, e.g., fluidically connect, components of the devices, and electrophoresing or otherwise propelling a sample through portions of the devices. In some embodiments, the disclosed methods include detecting an analyte and/or analyzing properties of a sample, such as one or more characteristics of an analyte in a sample. The analyte of interest can be a charged molecule or can be modified to be charged using, for example, one or more ionic moieties.

Abstract: Methods of detecting a target analyte in a sample are provided. Aspects of the method include: (a) contacting the sample with (i) a first capture agent that specifically binds the target analyte and (ii) a reporter complex under conditions sufficient to produce a sandwich complex; (b) separating the sandwich complex from the sample; and (c) releasing a detectable tag from the sandwich complex. The reporter complex may include a first specific binding member linked to a second capture agent that specifically binds the target analyte, and a second specific binding member specifically bound to the first specific binding member. In some cases, the second specific binding member is linked to a detectable tag. The releasing step may be achieved using a displacement binding member that is complementary to the first or second specific binding member. Also provided are compositions, systems and kits for practicing the subject methods.

Abstract: The technology provided herein generally relates to reusable detection surfaces and methods for reusing a detection surface after using the detection surface in an assay for an analyte.

Abstract: The invention pertains to bioconjugation systems comprising sterically constrained cis-diols and borates.

Abstract: The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.

Abstract: The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.

Abstract: The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.

Abstract: The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.

Abstract: The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.

Abstract: The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.

Abstract: The present invention provides methods for high-throughput screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve measuring the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA conformation.

Abstract: The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.

Abstract: The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.

Abstract: An n.times.m.times.p array of different chemical compounds, each having the following scaffold structure: ##STR1## wherein n, m and p are integers, A, B and C are organic structural moieties representing diversity elements. The novel compounds present in this array are useful as inhibitors of binding of Rev protein to a Rev response element.